The US drug supply chain has become a major national concern. Policymakers, healthcare providers, and pharmacy leaders now recognize the risks tied to foreign medicine manufacturing. As a result, the Centers for Medicare & Medicaid Services (CMS) is exploring new ways to strengthen domestic pharmaceutical production and improve supply chain resilience.
A recent discussion with Tim Casey, Senior Director of Government Affairs at USP, highlighted why CMS is reviewing medicine sourcing policies and how these reforms could reshape healthcare delivery across the United States. The conversation also revealed how pharmacists and hospitals continue to struggle with medicine shortages, rising operational pressure, and quality concerns.
Why CMS Is Reviewing Drug Supply Chains
CMS recently requested public comments regarding pharmaceutical supply chain vulnerabilities. According to Tim Casey, this move reflects growing bipartisan concern about national security and healthcare stability.
Lawmakers increasingly worry about America’s dependence on overseas suppliers for critical medicines and pharmaceutical ingredients. Several congressional committees have already examined these risks through hearings and investigations. Consequently, healthcare leaders expect additional legislation focused on domestic manufacturing and medicine security.
USP submitted comments because the organization has prioritized supply chain resilience for years. The organization recently launched a Resiliency Center and expanded the USP Medicine Supply Map platform. These tools help healthcare stakeholders identify supply chain risks, monitor manufacturing dependencies, and improve visibility across the pharmaceutical ecosystem.
Furthermore, policymakers now believe CMS reimbursement policies can influence how medicines are sourced and manufactured. Therefore, reimbursement reform may become one of the strongest tools for reducing future shortages.
Growing Concerns Over Drug Shortages
Drug shortages continue to create serious challenges across the healthcare industry. Hospitals and pharmacies often struggle to secure essential medicines, especially sterile injectable generics used in inpatient care.
Why Generic Injectables Face Higher Risk
Generic drug manufacturers typically operate on thin profit margins. In addition, injectable medicines require highly complex manufacturing processes. Because of these pressures, manufacturers frequently shift production overseas to reduce costs.
However, this strategy creates new vulnerabilities. Supplier consolidation, offshoring, and limited production capacity increase the risk of shortages when disruptions occur.
According to USP data, injectable medicines represent a significant portion of the organization’s Vulnerable Medicines List for 2025. These shortages can delay treatments, increase patient complications, and even raise mortality risks.
Operational Pressure on Hospitals and Pharmacies
Healthcare providers face major operational burdens during shortages. Pharmacists often spend hours locating alternative therapies or managing limited inventories. Meanwhile, hospitals experience increased labor costs and workflow disruptions.
Additionally, healthcare workers face higher levels of stress and burnout when medicine availability becomes unpredictable. As shortages continue, healthcare organizations must devote more resources to supply management instead of direct patient care.
How CMS Can Improve Medicine Manufacturing
CMS reimbursement systems significantly influence purchasing behavior throughout healthcare. In many inpatient settings, hospitals receive bundled payments tied to patient diagnoses. As a result, providers often prioritize the lowest-cost generic medications.
The Problem With Lowest-Cost Purchasing
Low-cost purchasing strategies can unintentionally weaken the pharmaceutical supply chain. Generic drug manufacturers already operate with limited margins. Therefore, constant pricing pressure encourages companies to move production overseas or exit the market entirely.
Over time, fewer manufacturers remain in the market. This consolidation reduces competition and increases supply chain fragility.
A New Resilience-Based Approach
USP recommends a resilience-focused reimbursement model. The organization’s Drug Supply Chain Resilience Initiative (DSCRI) proposes benchmarks that evaluate manufacturers based on quality, reliability, and supply chain stability.
Under this approach, CMS could reward manufacturers that invest in domestic production and resilient operations. Consequently, healthcare systems would gain stronger incentives to prioritize long-term reliability rather than short-term savings.
This model could also encourage sustainable pricing for generic medicines while supporting domestic pharmaceutical manufacturing growth.
The Role of Transparency and Quality Standards
Transparency remains one of the most important components of supply chain reform. Greater visibility allows manufacturers, healthcare providers, and policymakers to identify weaknesses before shortages occur.
Improving Supply Chain Visibility
Supply chain mapping tools help stakeholders detect single-source dependencies and upstream bottlenecks. These insights allow organizations to create mitigation plans and diversify sourcing strategies.
Moreover, visibility should extend beyond medicines already experiencing shortages. Even commonly used drugs may rely on limited suppliers for active ingredients or raw materials.
Strengthening Overseas Quality Oversight
CMS may also support stronger quality standards for foreign manufacturers. Some countries restrict unannounced FDA inspections, which raises concerns about product consistency and compliance.
Therefore, CMS could encourage healthcare systems to purchase medicines from suppliers participating in validated testing and quality verification programs. These measures would improve confidence in imported medicines while promoting higher manufacturing standards globally.
Impact on Pharmacists and Healthcare Providers
Pharmacists remain at the center of the drug shortage crisis. They regularly manage inventory disruptions, coordinate alternative treatments, and communicate with care teams during shortages.
Healthcare providers also face increasing administrative pressure due to reimbursement changes and supply instability. However, experts believe these reforms may create long-term improvements for patient care and pharmaceutical reliability.
In addition, stronger domestic manufacturing could reduce dependence on foreign suppliers and improve emergency preparedness across the healthcare system.
Bipartisan Momentum for Healthcare Reform
Unlike many healthcare issues, pharmaceutical supply chain reform has gained bipartisan support. Both political parties recognize the national security risks associated with foreign dependence for essential medicines.
Consequently, CMS actions may represent an early step toward broader legislative reform. Healthcare leaders believe this rare bipartisan alignment could create meaningful policy changes over the next several years.
Future Outlook for the US Drug Supply Chain
The pharmaceutical industry now stands at a critical turning point. Policymakers increasingly understand that low-cost purchasing alone cannot ensure stable medicine access.
Future reforms will likely focus on resilience, transparency, and domestic production incentives. If implemented effectively, these strategies could reduce shortages, improve patient outcomes, and strengthen healthcare infrastructure nationwide.
Conclusion
CMS’s growing involvement in pharmaceutical supply chain reform signals a major shift in healthcare policy. Drug shortages, foreign manufacturing dependence, and quality concerns have pushed policymakers to rethink how medicines are sourced and reimbursed.
Tim Casey’s insights highlight the urgent need for resilient manufacturing systems and transparent supply chains. As bipartisan momentum continues to build, CMS could play a vital role in creating a safer and more reliable pharmaceutical future for patients, pharmacists, and healthcare providers alike.
